Scholarlink

Purpose <p>The downregulated level of miR-342-3p has been reported in various kinds of human malignancies. It remains unclear the biological function of miR-342-3p in pappillary thyroid carcinoma (PTC). In this study, we assess the expression pattern of miR-342-3p and determine its potential role as biomarker in PTC, furthermore investigate its biological role during tumorigenesis.</p> Methods <p>The quantitative real-time PCR (qRT-PCR) was performed to measure the expression of miR-342-3p in 36 PTC tissue and in two human PTC cell lines (TPC-1 and B-CPAP). miR-342-3p mimic/inhibitor and si-FOXQ1 were transfected into TPC-1 and B-CPAP cells. The effects of miR-342-3p on the proliferation, invasion and migration of PTC cells were evaluated by Cell Counting Kit 8 (CCK-8), transwell and scratch healing assays. Flow cytometry analysis was performed to examine cell cycle and apoptosis. Expression levels of FOXQ1 in cells were assessed using Western blotting. The relationship between miR-342-3p and FOXQ1 was explored by Dual-luciferase reporter assay.</p> Results <p>Our findings revealed that miR-342-3p was low expressed in PTC tissue specimens and cell lines. Decreased expression of miR-342-3p was related to the AJCC stage. Meanwhile, the area under the receiver operating characteristic (ROC) was 0.714 (95%CI = 0.576–0.853), with a sensitivity of 63.9%, specificity of 69.4%, Youden index of 0.333 at cut-off value of 0.78. Ectopic upregulation of miR-342-3p and knockdown of FOXQ1 determined a reduction of PTC cell proliferation, migration, invasion, induced apoptosis in TPC-1 cells. Silencing miR-342-3p led to the opposite results. Additionally, FOXQ1 was found to be a target of miR-342-3p and this correlation was confirmed by dual-luciferase assay and Western blot.</p> Conclusions <p>In the present study, we demonstrate that miR-342-3p may be a novel potential marker for the diagnosis in PTC. Our findings suggest that miR-342-3p acts as tumor suppressor that plays an important role in PTC progression through targeting FOXQ1 signaling pathway, which indicates that miR-342-3p/FOXQ1 could be a therapeutic target for PTC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MiR-342-3p is a novel biomarker for the diagnosis and regulates tumorigenesis in thyroid papillary cancer through FOXQ1

  • 期刊论文

  • 发表日期：

    2026年4月1日

查看全文
  • Ying Li,
  • Wei Chen,
  • Ling Zhang,
  • Yan Zeng,
  • Yun Wang,
  • Yan-li Zhang,
  • Li Li,
  • Huaiyin Shi

摘要

Purpose

The downregulated level of miR-342-3p has been reported in various kinds of human malignancies. It remains unclear the biological function of miR-342-3p in pappillary thyroid carcinoma (PTC). In this study, we assess the expression pattern of miR-342-3p and determine its potential role as biomarker in PTC, furthermore investigate its biological role during tumorigenesis.

Methods

The quantitative real-time PCR (qRT-PCR) was performed to measure the expression of miR-342-3p in 36 PTC tissue and in two human PTC cell lines (TPC-1 and B-CPAP). miR-342-3p mimic/inhibitor and si-FOXQ1 were transfected into TPC-1 and B-CPAP cells. The effects of miR-342-3p on the proliferation, invasion and migration of PTC cells were evaluated by Cell Counting Kit 8 (CCK-8), transwell and scratch healing assays. Flow cytometry analysis was performed to examine cell cycle and apoptosis. Expression levels of FOXQ1 in cells were assessed using Western blotting. The relationship between miR-342-3p and FOXQ1 was explored by Dual-luciferase reporter assay.

Results

Our findings revealed that miR-342-3p was low expressed in PTC tissue specimens and cell lines. Decreased expression of miR-342-3p was related to the AJCC stage. Meanwhile, the area under the receiver operating characteristic (ROC) was 0.714 (95%CI = 0.576–0.853), with a sensitivity of 63.9%, specificity of 69.4%, Youden index of 0.333 at cut-off value of 0.78. Ectopic upregulation of miR-342-3p and knockdown of FOXQ1 determined a reduction of PTC cell proliferation, migration, invasion, induced apoptosis in TPC-1 cells. Silencing miR-342-3p led to the opposite results. Additionally, FOXQ1 was found to be a target of miR-342-3p and this correlation was confirmed by dual-luciferase assay and Western blot.

Conclusions

In the present study, we demonstrate that miR-342-3p may be a novel potential marker for the diagnosis in PTC. Our findings suggest that miR-342-3p acts as tumor suppressor that plays an important role in PTC progression through targeting FOXQ1 signaling pathway, which indicates that miR-342-3p/FOXQ1 could be a therapeutic target for PTC.